The purpose of this dissertation is to determine the intrinsic value of Grifols, a leading pharmaceutical company that manufactures plasma-derived medicines. The authors have conducted a fundamental analysis of Grifols by examining the macro and microeconomic factors that affect the environment it operates in, the competitive landscape, the corporate strategy, and the annual accounts of the company. Subsequently, they built their discounted cash flow (DCF) valuation model in Excel to calculate the intrinsic value of Grifols. They found that Grifols’ strong financial performance and its privileged access to sources of finance allows it to sustainably grow faster than competitors. Their results indicate that Grifols has an intrinsic value of €28.33 per share, which is higher than the current market value of €27.92 per share. The authors discover that Grifols’ economic moat will widen due to its collaboration with the U.S. government in the wake of COVID-19 and particularly due to its strategic initiative to expand to China. The already robust financial position is on track for sustained growth. Therefore, they firmly conclude that it is considered undervalued. The authors unanimously recommend potential investors to buy Grifols’ shares.
The purpose of this dissertation is to determine the intrinsic value of Grifols, a leading pharmaceutical company that manufactures plasma-derived medicines. The authors have conducted a fundamental analysis of Grifols by examining the macro and microeconomic factors that affect the environment it operates in, the competitive landscape, the corporate strategy, and the annual accounts of the company. Subsequently, they built their discounted cash flow (DCF) valuation model in Excel to calculate the intrinsic value of Grifols. They found that Grifols’ strong financial performance and its privileged access to sources of finance allows it to sustainably grow faster than competitors. Their results indicate that Grifols has an intrinsic value of €28.33 per share, which is higher than the current market value of €27.92 per share. The authors discover that Grifols’ economic moat will widen due to its collaboration with the U.S. government in the wake of COVID-19 and particularly due to its strategic initiative to expand to China. The already robust financial position is on track for sustained growth. Therefore, they firmly conclude that it is considered undervalued. The authors unanimously recommend potential investors to buy Grifols’ shares.
Through a detailed historical and empirical account of post-independence years, this book offers a new assessment of the role of the judiciary in Pakistani politics. Instead of seeing the judiciary as helpless or struggling against an authoritarian state, it argues that the judiciary has been a crucial link in the creation of state and political inequality in Pakistan. This rubs against the central role given to the judiciary in developing countries to fix the ‘corrupt politicians and stubborn bureaucracies’ in the World Bank’s ‘Good Governance’ paradigm and rule of law initiatives. It also challenges the contemporary legal and judicial discourse that extols the virtues of Public Interest Litigation. While the book’s core analysis is a critique of the contemporary liberal legal project, it also adds to the critical tradition of social theory by linking political economy to a social theory of law. The theoretical aspect of the study is applicable to any developing society whose judiciary is going through foreign-sponsored ‘rule of law’ judicial reforms.
Thank you for visiting our website. Would you like to provide feedback on how we could improve your experience?
This site does not use any third party cookies with one exception — it uses cookies from Google to deliver its services and to analyze traffic.Learn More.